Stock Track | Dr Reddy's Laboratories Soars 5.94% on Generic Ozempic Launch Plans in Canada

Stock Track05-13

Dr Reddy's Laboratories (RDY) saw its stock surge 5.94% over the past 24 hours, significantly outperforming the broader market during Tuesday's session.

The sharp rise appears to be driven by the company's announcement that it plans to launch a generic version of Novo Nordisk's blockbuster diabetes and weight-loss drug, Ozempic, in Canada this month. This move is expected to open up a substantial new revenue stream for the pharmaceutical company in a competitive market.

This positive development comes despite the company recently reporting quarterly earnings that missed analyst estimates, with revenue falling 11.5% year-over-year. The market's focus has shifted to the long-term growth potential offered by the generic Ozempic launch.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1172853072?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-13 11:49","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1172853072","market":"nz","top_or_hot":-1,"title":"Stock Track | Dr Reddy's Laboratories Soars 5.94% on Generic Ozempic Launch Plans in Canada","media":"Stock Track","content":"<p>Dr Reddy's Laboratories (RDY) saw its stock surge 5.94% over the past 24 hours, significantly outperforming the broader market during Tuesday's session.</p><p>The sharp rise appears to be driven by the company's announcement that it plans to launch a generic version of Novo Nordisk's blockbuster diabetes and weight-loss drug, Ozempic, in Canada this month. This move is expected to open up a substantial new revenue stream for the pharmaceutical company in a competitive market.</p><p>This positive development comes despite the company recently reporting quarterly earnings that missed analyst estimates, with revenue falling 11.5% year-over-year. The market's focus has shifted to the long-term growth potential offered by the generic Ozempic launch.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Dr Reddy's Laboratories Soars 5.94% on Generic Ozempic Launch Plans in Canada</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Dr Reddy's Laboratories Soars 5.94% on Generic Ozempic Launch Plans in Canada\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-05-13 11:49</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Dr Reddy's Laboratories (RDY) saw its stock surge 5.94% over the past 24 hours, significantly outperforming the broader market during Tuesday's session.</p><p>The sharp rise appears to be driven by the company's announcement that it plans to launch a generic version of Novo Nordisk's blockbuster diabetes and weight-loss drug, Ozempic, in Canada this month. This move is expected to open up a substantial new revenue stream for the pharmaceutical company in a competitive market.</p><p>This positive development comes despite the company recently reporting quarterly earnings that missed analyst estimates, with revenue falling 11.5% year-over-year. The market's focus has shifted to the long-term growth potential offered by the generic Ozempic launch.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"RDY","symbol_name":"如瑞迪博士","start_time":0,"source_url":"","article_id":"1172853072","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1172853072","pubTimestamp":1778644159,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Dr Reddy's Laboratories (RDY) saw its stock surge 5.94% over the past 24 hours, significantly outperforming the broader market during Tuesday's session.The sharp rise appears to be driven by the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"RDY":"如瑞迪博士"},"translate_title":"股票追踪|Dr Reddy's Laboratories因仿制药Ozempic计划在加拿大上市而飙升5.94%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RDY":1},"content_text":"Dr Reddy's Laboratories (RDY) saw its stock surge 5.94% over the past 24 hours, significantly outperforming the broader market during Tuesday's session.The sharp rise appears to be driven by the company's announcement that it plans to launch a generic version of Novo Nordisk's blockbuster diabetes and weight-loss drug, Ozempic, in Canada this month. This move is expected to open up a substantial new revenue stream for the pharmaceutical company in a competitive market.This positive development comes despite the company recently reporting quarterly earnings that missed analyst estimates, with revenue falling 11.5% year-over-year. The market's focus has shifted to the long-term growth potential offered by the generic Ozempic launch.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1172853072","isCrawlerRequest":true}